MOTS-C
Investigational metabolic and longevity research
Evidence: Primarily preclinical
Administration: No approved route
Read Review →Evidence and regulatory context for peptide-based treatments connected to longevity.
CJC-1295
Investigational hormonal and body-composition research
Evidence: Limited clinical data
Administration: No approved route
Read Review →Ipamorelin
Investigational hormonal and body-composition research
Evidence: Limited human trials
Administration: No approved route
Read Review →Established / approved options
No peptide treatment is presented as FDA-approved for general longevity.
Being researched
MOTS-C and other longevity claims remain investigational and should not be presented as established treatment benefits.
How to use this page
Established options appear before experimental compounds. Goal relevance never overrides regulatory status or evidence quality.
Next step
Open the relevant treatment review for sources, risks, contraindications, and evidence gaps.
MyPeptideQuest
Information only. Not medical advice. No dosing or self-treatment instructions are provided.